Portal de Periódicos da CAPES

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

2021; American Association for the Advancement of Science; Volume: 373; Issue: 6561 Linguagem: Inglês

10.1126/science.abj4176

1095-9203

Amarendra Pegu, Sarah O’Connell, Stephen D. Schmidt, Sijy O’Dell, Chloe Adrienna Talana, Lilin Lai, Jim Albert, Evan J. Anderson, Hamilton Bennett, Kizzmekia S. Corbett, Britta Flach, Lisa A. Jackson, Brett Leav, Julie E. Ledgerwood, Catherine J. Luke, Mat Makowski, Martha Nason, Paul C. Roberts, Mario Roederer, Paulina A. Rebolledo, Christina A. Rostad, Nadine Rouphael, Wei Shi, Lingshu Wang, Alicia T. Widge, Eun Sung Yang, John H. Beigel, Barney S. Graham, John R. Mascola, Mehul S. Suthar, Adrian B. McDermott, Nicole A. Doria‐Rose, Jae Arega, John H. Beigel, Wendy Buchanan, Mohammed Elsafy, Binh Hoang, Rebecca Lampley, Aparna Kolhekar, Hyung Il Koo, Catherine J. Luke, Mamodikoe Makhene, Seema Nayak, Rhonda Pikaart-Tautges, Paul C. Roberts, Janie Russell, Elisa Sindall, Jim Albert, Pratap Kunwar, Mat Makowski, Evan J. Anderson, Amer Bechnak, Mary Bower, Andrés Camacho-González, Matthew H. Collins, Ana Drobeniuc, Venkata Viswanadh Edara, Srilatha Edupuganti, Katharine Floyd, Theda Gibson, Cassie M. Grimsley Ackerley, Brandi Johnson, Satoshi Kamidani, Carol Kao, Colleen F. Kelley, Lilin Lai, Hollie Macenczak, Michele Paine McCullough, Etza Peters, Varun K. Phadke, Paulina A. Rebolledo, Christina A. Rostad, Nadine Rouphael, Erin M. Scherer, Amy C Sherman, Kathy Stephens, Mehul S. Suthar, Mehgan Teherani, Jessica Traenkner, Juton Winston, İnci Yıldırım, Lee Barr, Joyce Benoit, Barbara Carste, Joe Choe, Maya Dunstan, Roxanne Erolin, Jana ffitch, Colin Fields, Lisa A. Jackson, Erika Kiniry, Susan Lasicka, Stella E. Lee, M. Nguyen, Stephanie Pimienta, Janice Suyehira, Michael M. Witte, Hamilton Bennett, Nedim Emil Altaras, Andrea Carfı́, Marjorie Hurley, Brett Leav, Rolando Pajón, Wellington Sun, Tal Zaks, Rhea N. Coler, Sasha E. Larsen, Kathleen M. Neuzil, Lisa C. Lindesmith, David R. Martinez, Jennifer E. Munt, Michael L. Mallory, Caitlin E. Edwards, Ralph S. Baric, Nina M. Berkowitz, Eli Boritz, Kevin Carlton, Kizzmekia S. Corbett, Pamela Costner, Adrian Creanga, Nicole A. Doria‐Rose, Daniel C. Douek, Britta Flach, Martin R. Gaudinski, Ingelise J. Gordon, Barney S. Graham, LaSonji A. Holman, Julie E. Ledgerwood, Kwanyee Leung, Bob C. Lin, Mark K. Louder, John R. Mascola, Adrian B. McDermott, Kaitlyn M. Morabito, Laura Novik, Sarah O’Connell, Sijy O’Dell, Marcelino Padilla, Amarendra Pegu, Stephen D. Schmidt, Wei Shi, Phillip A. Swanson, Chloe Adrienna Talana, Lingshu Wang, Alicia T. Widge, Eun Sung Yang, Yi Zhang, James D. Chappell, Mark R. Denison, Tia M. Hughes, Xiaotao Lu, Andrea J. Pruijssers, Laura J. Stevens, Christine M. Posavad, Michael Gale, Vineet D. Menachery, Pei‐Yong Shi,

Animal Virus Infections Studies

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.